![]() Neuralgia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment (Drug-Based, Surgery), By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), By Region & Competition, 2020-2030F
Global Neuralgia Treatment Market was valued at USD 1.21 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.84% through 2030. The Global Neuralg... もっと見る
SummaryGlobal Neuralgia Treatment Market was valued at USD 1.21 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.84% through 2030. The Global Neuralgia Treatment Market in 2023 is characterized by significant growth and advancements in the diagnosis and management of neuralgia-related conditions.The global neuralgia treatment market is driven by factors such as the rising prevalence of neurological disorders, increasing geriatric population, advancements in drug development, growing awareness about pain management, enhanced healthcare access, and the rising demand for effective treatments for chronic pain conditions like trigeminal neuralgia and postherpetic neuralgia. For instance, in June 2024, the Australian Government committed USD 19.6 million from the Medical Research Future Fund to improve primary healthcare, emphasizing chronic pain and multidisciplinary care. USD 8.8 million will support chronic pain initiatives, focusing on rural communities and adapting programs to reduce disability, enhancing healthcare access and outcomes.Key Market Drivers Rising Prevalence of Neuralgia-Related Conditions Neuralgia, a condition characterized by excruciating pain along nerve pathways, affects millions of individuals worldwide, significantly impacting their quality of life. While neuralgia encompasses various forms, including trigeminal neuralgia, postherpetic neuralgia, and diabetic neuropathy, one common trend is the rising prevalence of neuralgia-related conditions. This growing prevalence represents both a significant challenge and an opportunity for the healthcare industry. According to a 2024 Multiple Sclerosis (MS) Society study, over 150,000 people in the UK are living with multiple sclerosis (MS), with the increase attributed to improved diagnoses and longer life expectancies rather than a higher risk. The regional prevalence is: around 123,000 in England (1 in 450), 6,100 in Wales (1 in 500), 5,300 in Northern Ireland (1 in 350), and 17,400 in Scotland (1 in 300). Annually, more than 7,100 new cases are diagnosed, which averages to about 135 weekly. Key Market Challenges Underdiagnosis and Misdiagnosis A major challenge is the underdiagnosis and misdiagnosis of neuralgia-related conditions. Many individuals endure their symptoms without seeking medical attention, often because they are unaware of their condition or its severity. Misdiagnosis can lead to inappropriate treatments and delays in receiving proper care. Key Market Trends Advanced Diagnostic Tools Early and accurate diagnosis is crucial for effective neuralgia treatment. The development of more sophisticated diagnostic tools, such as high-resolution imaging, nerve conduction studies, and genetic testing, will enable healthcare professionals to identify neuralgia-related conditions with greater precision. Timely diagnosis will lead to more targeted treatments. Key Market Players • GSK PLC • Pfizer Inc • Novartis AG • Biogen Inc • Cadila Pharmaceuticals Ltd • Lundbeck Pharmaceuticals Ltd • Zydus Group (Cadila Healthcare Limited) • Eli Lily and Company • Allergan Inc. • Baxter International Inc. Report Scope: In this report, the Global Neuralgia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: • Neuralgia Treatment Market, By Treatment: o Drug-Based o Surgery • Neuralgia Treatment Market, By Indication: o Diabetic Neuropathy o Intercostal Neuralgia o Occipital Neuralgia o Peripheral Neuralgia o Postherpetic Neuralgia o Trigeminal Neuralgia • Neuralgia Treatment Market, By Distribution Channel: o Hospital Pharmacies o Online Pharmacies o Retail Pharmacies • Neuralgia Treatment Market, By Region: o North America § United States § Canada § Mexico o Europe § Germany § United Kingdom § France § Italy § Spain o Asia-Pacific § China § Japan § India § Australia § South Korea o South America § Brazil § Argentina § Colombia o Middle East & Africa § South Africa § Saudi Arabia § UAE § Kuwait Competitive Landscape Company Profiles: Detailed analysis of the major companies present in the Global Neuralgia Treatment Market. Available Customizations: Global Neuralgia Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: Company Information • Detailed analysis and profiling of additional market players (up to five). Table of Contents1. Product Overview1.1. Market Definition 1.2. Scope of the Market 1.2.1. Markets Covered 1.2.2. Years Considered for Study 1.2.3. Key Market Segmentations 2. Research Methodology 2.1. Objective of the Study 2.2. Baseline Methodology 2.3. Key Industry Partners 2.4. Major Association and Secondary Sources 2.5. Forecasting Methodology 2.6. Data Triangulation & Validation 2.7. Assumptions and Limitations 3. Executive Summary 3.1. Overview of the Market 3.2. Overview of Key Market Segmentations 3.3. Overview of Key Market Players 3.4. Overview of Key Regions/Countries 3.5. Overview of Market Drivers, Challenges, Trends 4. Voice of Customer 5. Global Neuralgia Treatment Market Outlook 5.1. Market Size & Forecast 5.1.1. By Value 5.2. Market Share & Forecast 5.2.1. By Treatment (Drug-Based, Surgery) 5.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia) 5.2.3. By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) 5.2.4. By Region 5.2.5. By Company (2024) 5.3. Product Market Map 5.3.1. By Treatment 5.3.2. By Indication 5.3.3. By Distribution Channel 5.3.4. By Region 6. North America Neuralgia Treatment Market Outlook 6.1. Market Size & Forecast 6.1.1. By Value 6.2. Market Share & Forecast 6.2.1. By Treatment (Drug-Based, Surgery) 6.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia) 6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) 6.2.4. By Country 6.3. North America: Country Analysis 6.3.1. United States Neuralgia Treatment Market Outlook 6.3.1.1. Market Size & Forecast 6.3.1.1.1. By Value 6.3.1.2. Market Share & Forecast 6.3.1.2.1. By Treatment 6.3.1.2.2. By Indication 6.3.1.2.3. By Distribution Channel 6.3.2. Canada Neuralgia Treatment Market Outlook 6.3.2.1. Market Size & Forecast 6.3.2.1.1. By Value 6.3.2.2. Market Share & Forecast 6.3.2.2.1. By Treatment 6.3.2.2.2. By Indication 6.3.2.2.3. By Distribution Channel 6.3.3. Mexico Neuralgia Treatment Market Outlook 6.3.3.1. Market Size & Forecast 6.3.3.1.1. By Value 6.3.3.2. Market Share & Forecast 6.3.3.2.1. By Treatment 6.3.3.2.2. By Indication 6.3.3.2.3. By Distribution Channel 7. Europe Neuralgia Treatment Market Outlook 7.1. Market Size & Forecast 7.1.1. By Value 7.2. Market Share & Forecast 7.2.1. By Treatment (Drug-Based, Surgery) 7.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia) 7.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) 7.2.4. By Country 7.3. Europe: Country Analysis 7.3.1. Germany Neuralgia Treatment Market Outlook 7.3.1.1. Market Size & Forecast 7.3.1.1.1. By Value 7.3.1.2. Market Share & Forecast 7.3.1.2.1. By Treatment 7.3.1.2.2. By Indication 7.3.1.2.3. By Distribution Channel 7.3.2. United Kingdom Neuralgia Treatment Market Outlook 7.3.2.1. Market Size & Forecast 7.3.2.1.1. By Value 7.3.2.2. Market Share & Forecast 7.3.2.2.1. By Treatment 7.3.2.2.2. By Indication 7.3.2.2.3. By Distribution Channel 7.3.3. France Neuralgia Treatment Market Outlook 7.3.3.1. Market Size & Forecast 7.3.3.1.1. By Value 7.3.3.2. Market Share & Forecast 7.3.3.2.1. By Treatment 7.3.3.2.2. By Indication 7.3.3.2.3. By Distribution Channel 7.3.4. Italy Neuralgia Treatment Market Outlook 7.3.4.1. Market Size & Forecast 7.3.4.1.1. By Value 7.3.4.2. Market Share & Forecast 7.3.4.2.1. By Treatment 7.3.4.2.2. By Indication 7.3.4.2.3. By Distribution Channel 7.3.5. Spain Neuralgia Treatment Market Outlook 7.3.5.1. Market Size & Forecast 7.3.5.1.1. By Value 7.3.5.2. Market Share & Forecast 7.3.5.2.1. By Treatment 7.3.5.2.2. By Indication 7.3.5.2.3. By Distribution Channel 8. Asia-Pacific Neuralgia Treatment Market Outlook 8.1. Market Size & Forecast 8.1.1. By Value 8.2. Market Share & Forecast 8.2.1. By Treatment (Drug-Based, Surgery) 8.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia) 8.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) 8.2.4. By Country 8.3. Asia-Pacific: Country Analysis 8.3.1. China Neuralgia Treatment Market Outlook 8.3.1.1. Market Size & Forecast 8.3.1.1.1. By Value 8.3.1.2. Market Share & Forecast 8.3.1.2.1. By Treatment 8.3.1.2.2. By Indication 8.3.1.2.3. By Distribution Channel 8.3.2. Japan Neuralgia Treatment Market Outlook 8.3.2.1. Market Size & Forecast 8.3.2.1.1. By Value 8.3.2.2. Market Share & Forecast 8.3.2.2.1. By Treatment 8.3.2.2.2. By Indication 8.3.2.2.3. By Distribution Channel 8.3.3. India Neuralgia Treatment Market Outlook 8.3.3.1. Market Size & Forecast 8.3.3.1.1. By Value 8.3.3.2. Market Share & Forecast 8.3.3.2.1. By Treatment 8.3.3.2.2. By Indication 8.3.3.2.3. By Distribution Channel 8.3.4. Australia Neuralgia Treatment Market Outlook 8.3.4.1. Market Size & Forecast 8.3.4.1.1. By Value 8.3.4.2. Market Share & Forecast 8.3.4.2.1. By Treatment 8.3.4.2.2. By Indication 8.3.4.2.3. By Distribution Channel 8.3.5. South Korea Neuralgia Treatment Market Outlook 8.3.5.1. Market Size & Forecast 8.3.5.1.1. By Value 8.3.5.2. Market Share & Forecast 8.3.5.2.1. By Treatment 8.3.5.2.2. By Indication 8.3.5.2.3. By Distribution Channel 9. South America Neuralgia Treatment Market Outlook 9.1. Market Size & Forecast 9.1.1. By Value 9.2. Market Share & Forecast 9.2.1. By Treatment (Drug-Based, Surgery) 9.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia) 9.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) 9.2.4. By Country 9.3. South America: Country Analysis 9.3.1. Brazil Neuralgia Treatment Market Outlook 9.3.1.1. Market Size & Forecast 9.3.1.1.1. By Value 9.3.1.2. Market Share & Forecast 9.3.1.2.1. By Treatment 9.3.1.2.2. By Indication 9.3.1.2.3. By Distribution Channel 9.3.2. Argentina Neuralgia Treatment Market Outlook 9.3.2.1. Market Size & Forecast 9.3.2.1.1. By Value 9.3.2.2. Market Share & Forecast 9.3.2.2.1. By Treatment 9.3.2.2.2. By Indication 9.3.2.2.3. By Distribution Channel 9.3.3. Colombia Neuralgia Treatment Market Outlook 9.3.3.1. Market Size & Forecast 9.3.3.1.1. By Value 9.3.3.2. Market Share & Forecast 9.3.3.2.1. By Treatment 9.3.3.2.2. By Indication 9.3.3.2.3. By Distribution Channel 10. Middle East and Africa Neuralgia Treatment Market Outlook 10.1. Market Size & Forecast 10.1.1. By Value 10.2. Market Share & Forecast 10.2.1. By Treatment (Drug-Based, Surgery) 10.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia) 10.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) 10.2.4. By Country 10.3. MEA: Country Analysis 10.3.1. South Africa Neuralgia Treatment Market Outlook 10.3.1.1. Market Size & Forecast 10.3.1.1.1. By Value 10.3.1.2. Market Share & Forecast 10.3.1.2.1. By Treatment 10.3.1.2.2. By Indication 10.3.1.2.3. By Distribution Channel 10.3.2. Saudi Arabia Neuralgia Treatment Market Outlook 10.3.2.1. Market Size & Forecast 10.3.2.1.1. By Value 10.3.2.2. Market Share & Forecast 10.3.2.2.1. By Treatment 10.3.2.2.2. By Indication 10.3.2.2.3. By Distribution Channel 10.3.3. UAE Neuralgia Treatment Market Outlook 10.3.3.1. Market Size & Forecast 10.3.3.1.1. By Value 10.3.3.2. Market Share & Forecast 10.3.3.2.1. By Treatment 10.3.3.2.2. By Indication 10.3.3.2.3. By Distribution Channel 10.3.4. Kuwait Neuralgia Treatment Market Outlook 10.3.4.1. Market Size & Forecast 10.3.4.1.1. By Value 10.3.4.2. Market Share & Forecast 10.3.4.2.1. By Treatment 10.3.4.2.2. By Indication 10.3.4.2.3. By Distribution Channel 11. Market Dynamics 11.1. Drivers 11.2. Challenges 12. Market Trends & Developments 12.1. Recent Development 12.2. Mergers & Acquisitions 12.3. Product Launches 13. Porter’s Five Forces Analysis 13.1. Competition in the Industry 13.2. Potential of New Entrants 13.3. Power of Suppliers 13.4. Power of Customers 13.5. Threat of Substitute Products 14. Competitive Landscape 14.1. GSK PLC 14.2. Pfizer Inc 14.3. Novartis AG 14.4. Biogen Inc 14.5. Cadila Pharmaceuticals Ltd 14.6. Lundbeck Pharmaceuticals Ltd 14.7. Zydus Group (Cadila Healthcare Limited) 14.8. Eli Lily and Company 14.9. Allergan Inc. 14.10. Baxter International Inc. 15. Strategic Recommendations 16. About Us & Disclaimer
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポート
TechSci Research社のヘルスケア分野での最新刊レポート
本レポートと同じKEY WORD(industry)の最新刊レポート
よくあるご質問TechSci Research社はどのような調査会社ですか?テックサイリサーチ(TechSci Research)は、カナダ、英国、インドに拠点を持ち、化学、IT、環境、消費財と小売、自動車、エネルギーと発電の市場など、多様な産業や地域を対象とした調査・出版活... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|